The EZH2 inhibitor tazemetostat mitigates HIV immune evasion, reduces reservoir formation, and promotes durable CD8+ T-cell revitalization
Andrea Gramatica, Itzayana G. Miller, Adam R. Ward, Khan Farzana, Tyler J. Kemmer, Jared Weiler, Tan Thinh Huynh, Paul Zumbo, Andrew P. Kurland, Louise Leyre, Yanqin Ren, Thaís Klevorn, Dennis C. Copertino, Uchenna K. Chukwukere, Callie Levinger, , R. Brad Jones
The paper shows that tazemetostat reduces HIV reservoirs and improves CD8+ T-cell function by increasing MHC-I expression and promoting anti-HIV immune responses.
Cell Reports · May 1, 2025Peer-reviewedImmunology